• Explore /
  • Poster
  • / Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.

Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.

Abstract Poster

Authors

null

Lena Unterrainer

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA

Lena Unterrainer , Andrea Farolfi , Florian Rosar , Chloé Santina Denis , Louise Emmett , Ivan de Kouchkovsky , Thomas A. Hope , Masatoshi Hotta , Andrei Gafita , Loic Djaileb , Johannes Czernin , Jeremie Calais

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5063)

DOI

10.1200/JCO.2023.41.16_suppl.5063

Abstract #

5063

Poster Bd #

157

Abstract Disclosures

Similar Posters

First Author: Ridvan Arda Demirci

First Author: Ruben Raychaudhuri

Poster

2023 ASCO Genitourinary Cancers Symposium

Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.

Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.

First Author: Michael Philip Sun

First Author: Scott T. Tagawa